// App-Quantinova.ai

: Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.

Researchers

Presenter

  • Christopher J. Hoimes

Principal Investigators

  • Yohann Loriot

  • Jens Bedke

  • Hiroyuki Nishiyama

  • Ritesh S. Kataria

  • Blanca Homet Moreno

  • Matt D. Galsky

Medical Centers

  • University of Tsukuba, Tsukuba, Japan

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Eberhard Karls University, Tubingen, Germany

  • Duke University, Durham, NC

Locations

  • Germany

  • Japan

  • France

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Enfortumab vedotin

  • Pembrolizumab

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT04700124

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved